Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NASDAQ:VTRS
Viatris (VTRS)
15.37
-0.00 (0.00%)
as of Jun 18, 2026, 7:59:59 pm Market Open.
23 watching
Financials 
Technical Analysis 0
DON'T BUY
Among the biggest losers on the S&P in 2021
#6, down 28%. It's a Pfizer generic drug spin-off. Bad timing--Biden wants to reign in generic drug pricing. VTRS expects no earnings growth this year or next. They hold patent drugs under pressure as more knock-offs hit the market. It's the ultimate value trap. It sells for less than 4x earnings, but this is usually a red flag. Better to buy big pharmas.
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Dec 22/20, Down 24%) By far the cheapest cost (and highest value) stock in their portfolio. A fist banging buy. They have drugs like the EpiPen and others for asthma. They pay a reasonable dividend and it trades at 4x earnings. Even at 8x, it would be very cheap. He is not concerned about legal issues surrounding the EpiPen - you simply need their product.
Lorne SteinbergOwned
Pharma & Healthcare
STRONG BUY
PE is around 5. Cheapest stock in his portfolio. First quarter, they underdelivered and the stock was punished. Last quarter, management delivered. He owns it for capital appreciation. Risk/reward is highly stacked in favour of the reward side. A bargain.
Lorne SteinbergOwned
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Dec 22/20, Down 17%) Incredibly cheap, core holding for him. In generics, with some coming off patent. Very solid pipeline. Last quarter was surprisingly strong. Solid dividend.
Lorne SteinbergOwned
Pharma & Healthcare
BUY
It is the cheapest stock he owns. They came to market and disappointed with their first quarter. The are being punished by the street. They are now a show-me stock. Little needs to go right for this company.
Lorne SteinbergOwned
Pharma & Healthcare
BUY
Q1 earnings disappointed. Around 6x earnings. A show-me stock. Incredibly cheap. Solid free cashflow generator. Solidly profitable. Not much has to go right to get a really good return. Everyone is pessimistic, which is usually a bullish sign.
Lorne SteinbergOwned
Pharma & Healthcare
TOP PICK
Brand new company from the merger if Mylan and Upjohn. Trades at 6x earnings and nobody has covered this. This stock will trade at 10-11x earnings, nearly doubling. This is his most compelling top pick today. The company is already generating profits and cash flow. They make Xoloft, Viagra, Lipotor mostly from Upjohn. They also have a pipeline of new drugs company. Seasoned managers. (Analysts’ price target is $22.43)
Lorne SteinbergOwned
Pharma & Healthcare
Showing 16 to 23 of 23 entries
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
